Skip to main content
SpringerLink
Log in

Precancerous Lesions of Endometrial Serous Carcinomas

  • Chapter
Precancerous Lesions of the Gynecologic Tract

  • 1214 Accesses

Abstract

The following section reviews the current state of knowledge on precancerous lesions of endometrial serous carcinoma and details all clinicopathologic aspects of the spectrum of putative precancerous and precursor lesions for serous carcinoma that has been proffered during the last quarter century.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93–108.

    Article  CAS  PubMed  Google Scholar 

  2. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  3. Huang CY, Tang YH, Chiang YC, Wang KL, Fu HC, Ke YM, Lau HY, Hsu KF, Wu CH, Cheng WF. Impact of management on the prognosis of pure uterine papillary serous cancer – a Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecol Oncol. 2014;133:221–8.

    Article  PubMed  Google Scholar 

  4. Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys. 2003;57:208–16.

    Article  PubMed  Google Scholar 

  5. Ball A, Chu P, Ghatage P, Nation J, Nelson G. The importance of surgical staging in women with uterine serous carcinoma: experience in a single institution reveals a survival benefit. J Obstet Gynaecol Can. 2014;36:1085–92.

    PubMed  Google Scholar 

  6. Chan JK, Loizzi V, Youssef M, Osann K, Rutgers J, Vasilev SA, Berman ML. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol. 2003;90:181–5.

    Article  PubMed  Google Scholar 

  7. Gehrig PA, Groben PA, Fowler Jr WC, Walton LA, Van Le L. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol. 2001;97:153–7.

    Article  CAS  PubMed  Google Scholar 

  8. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463–9.

    Article  PubMed  Google Scholar 

  9. Carcangiu ML, Tan LK, Chambers JT. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol. 1997;21:1507–14.

    Article  CAS  PubMed  Google Scholar 

  10. Semaan A, Mert I, Munkarah AR, Bandyopadhyay S, Mahdi HS, Winer IS, Nucci MR, Hussein Y, Quershi F, Hayek K, Tabassum F, Alosh B, Schultz DS, Cote ML, Vijver KK, Morris RT, Oliva E, Ali-Fehmi R. Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study. Int J Gynecol Pathol. 2013;32:181–7.

    Article  PubMed  Google Scholar 

  11. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797–806.

    Article  CAS  PubMed  Google Scholar 

  12. Hui P, Kelly M, O’Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol. 2005;18:75–82.

    Article  PubMed  Google Scholar 

  13. Schwartz PE. The management of serous papillary uterine cancer. Curr Opin Oncol. 2006;18:494–9.

    Article  PubMed  Google Scholar 

  14. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain III JR, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small Jr W, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes M. Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw. 2014;12:248–80.

    CAS  PubMed  Google Scholar 

  15. Boruta II DM, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142–53.

    Article  PubMed  Google Scholar 

  16. Zheng W, Xiang L, Fadare O, Kong B. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol. 2011;35:e1–14.

    Article  PubMed  Google Scholar 

  17. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol. 2009;2:411–32.

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Zhang X, Liang SX, Jia L, Chen N, Fadare O, Schwartz PE, Kong B, Zheng W. Molecular identification of “latent precancers” for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol. 2009;174:2000–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Jarboe EA, Pizer ES, Miron A, Monte N, Mutter GL, Crum CP. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol. 2009;22:345–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Nguyen TT, Hachisuga T, Urabe R, Kurita T, Kagami S, Kawagoe T, Shimajiri S, Nabeshima K. Significance of p53 expression in background endometrium in endometrial carcinoma. Virchows Arch. 2015;466(6):695–702.

    Article  CAS  PubMed  Google Scholar 

  21. Zheng W, Liang SX, Yu H, Rutherford T, Chambers SK, Schwartz PE. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol. 2004;12:207–23.

    Article  PubMed  Google Scholar 

  22. Liang SX, Chambers SK, Cheng L, Zhang S, Zhou Y, Zheng W. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol. 2004;12:319–31.

    Article  CAS  PubMed  Google Scholar 

  23. Zheng W, Liang SX, Yi X, Ulukus EC, Davis JR, Chambers SK. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol. 2007;26:38–52.

    Article  CAS  PubMed  Google Scholar 

  24. Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, Zheng W. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res. 2008;14:2263–9.

    Article  CAS  PubMed  Google Scholar 

  25. Fadare O, Zheng W. Endometrial Glandular Dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers. Diagn Pathol. 2008;3:6.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Yi X, Zheng W. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr Opin Obstet Gynecol. 2008;20:20–5.

    Article  PubMed  Google Scholar 

  27. Lee KR, Belinson JL. Recurrence in noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma. Am J Surg Pathol. 1991;15:965–73.

    Article  CAS  PubMed  Google Scholar 

  28. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16:600–10.

    Article  CAS  PubMed  Google Scholar 

  29. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol. 1995;19:417–32.

    Article  CAS  PubMed  Google Scholar 

  30. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260–7.

    Article  CAS  PubMed  Google Scholar 

  31. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol. 1998;22:1463–73.

    Article  CAS  PubMed  Google Scholar 

  32. Zheng W, Schwartz PE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol. 2005;96:579–82.

    Article  PubMed  Google Scholar 

  33. Hendrickson MR, Kempson RL. Surgical pathology of the uterine corpus. Volume 12, Major problems in surgical pathology. Philadelphia, PA: WB Saunders; 1980.

    Google Scholar 

  34. Tavassoli FA, Devilee P. World Health Organization Classification of tumors. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.

    Google Scholar 

  35. Tolcher MC, Swisher EM, Medeiros F, Lima JF, Hilderbrand JL, Donovan JL, Garcia RL, Cliby WA, Dowdy SC. Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma. Int J Gynecol Pathol. 2015;34:57–64.

    Article  CAS  PubMed  Google Scholar 

  36. Hou JY, McAndrew TC, Goldberg GL, Whitney K, Shahabi S. A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference? Reprod Sci. 2014;21:532–7.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Soslow RA, Pirog E, Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol. 2000;24:726–32.

    Article  CAS  PubMed  Google Scholar 

  38. Yan Z, Hui P. Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases. Appl Immunohistochem Mol Morphol. 2010;18:75–9.

    Article  CAS  PubMed  Google Scholar 

  39. Jia L, Yuan Z, Wang Y, Cragun JM, Kong B, Zheng W. Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma. Mod Pathol. 2015;28:118–27.

    Article  PubMed  Google Scholar 

  40. Baergen RN, Warren CD, Isacson C, Ellenson LH. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol. 2001;20:214–9.

    Article  CAS  PubMed  Google Scholar 

  41. Jarboe EA, Miron A, Carlson JW, Hirsch MS, Kindelberger D, Mutter GL, Crum CP, Nucci MR. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol. 2009;28:308–15.

    Article  PubMed  Google Scholar 

  42. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230–6.

    Article  PubMed  Google Scholar 

  43. Mingels MJ, van Ham MA, de Kievit IM, Snijders MP, van Tilborg AA, Bulten J, Massuger LF. Müllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol. Mod Pathol. 2014;27:1002–13.

    Article  PubMed  Google Scholar 

  44. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26:1268–74.

    Article  CAS  PubMed  Google Scholar 

  45. McCluggage WG, Connolly LE, McBride HA, Kalloger S, Gilks CB. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology. 2012;60:547–53.

    Article  PubMed  Google Scholar 

  46. Ono K, Hayashi H, Tateno M, Tanaka R, Suzuki R, Maruyama Y, Miyagi Y, Furuya M. Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: clinicopathological analysis of 6 patients. Int J Clin Exp Pathol. 2014;7:7979–88.

    PubMed Central  PubMed  Google Scholar 

  47. Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol. 2013;26:1605–12.

    Article  CAS  PubMed  Google Scholar 

  48. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304–15.

    Article  PubMed  Google Scholar 

  49. Chen N, Yi X, Abushahin N, Pang S, Zhang D, Kong B, Zheng W. Nrf2 expression in endometrial serous carcinomas and its precancers. Int J Clin Exp Pathol. 2010;4:85–96.

    PubMed Central  PubMed  Google Scholar 

  50. Vang R, Barner R, Wheeler DT, Strauss BL. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma. Int J Gynecol Pathol. 2004;23:223–33.

    Article  PubMed  Google Scholar 

  51. Fadare O, James S, Desouki MM, Khabele D. Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. Ann Diagn Pathol. 2013;17:430–3.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IM. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst. 2012;104:1503–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Kuhn E, Bahadirli-Talbott A, Shih IM. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol. 2014;27:1014–9.

    Article  CAS  PubMed  Google Scholar 

  54. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150:177–85.

    PubMed Central  CAS  PubMed  Google Scholar 

  55. Berman JJ, Albores-Saavedra J, Bostwick D, Delellis R, Eble J, Hamilton SR, Hruban RH, Mutter GL, Page D, Rohan T, Travis W, Henson DE. Precancer: a conceptual working definition – results of a Consensus Conference. Cancer Detect Prev. 2006;30:387–94.

    Article  PubMed  Google Scholar 

  56. Haley SL, Malhotra RK, Qiu S, Eltorky ME. The immunohistochemical profile of atypical eosinophilic syncytial changes vs serous carcinoma. Ann Diagn Pathol. 2011;15:402–6.

    Article  PubMed  Google Scholar 

  57. Renshaw IL, Fadare O. Infarcted endometrial polyps with glandular atypia: a potential diagnostic pitfall. Presented at The United States and Canadian Academy of Pathology (USCAP), San Diego, CA, March 1–7, 2014.

    Google Scholar 

  58. McCluggage WG, McBride HA. Papillary syncytial metaplasia associated with endometrial breakdown exhibits an immunophenotype that overlaps with uterine serous carcinoma. Int J Gynecol Pathol. 2012;31:206–10.

    Article  PubMed  Google Scholar 

  59. Fadare O, Zheng W. Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach. Am J Cancer Res. 2012;2:335–9.

    PubMed Central  PubMed  Google Scholar 

  60. Wild PJ, Ikenberg K, Fuchs TJ, Rechsteiner M, Georgiev S, Fankhauser N, Noske A, Roessle M, Caduff R, Dellas A, Fink D, Moch H, Krek W, Frew IJ. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med. 2012;4:808–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Chook YM, Blobel G. Karyopherins and nuclear import. Curr Opin Struct Biol. 2001;11:703–15.

    Article  CAS  PubMed  Google Scholar 

  62. Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, Rechsteiner M, Rueschoff JH, Caduff R, Dellas A, Obermann E, Fink D, Fuchs T, Krek W, Moch H, Frew IJ, Wild PJ. KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. J Pathol. 2014;234:239–52.

    CAS  PubMed  Google Scholar 

  63. Roberts JM, Cornall AM, Lamaro V, Tabrizi SN, Russell P. Endocervical adenocarcinoma in situ presenting in fundal endometrial polyp: the mother of all skip lesions. Int J Gynecol Pathol. 2015;34:228–31.

    Article  PubMed  Google Scholar 

  64. Bagby C, Ronnett BM, Yemelyanova A, Maleki Z, Kuhn E, Vang R. Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin. Int J Gynecol Pathol. 2013;32:433–43.

    Article  CAS  PubMed  Google Scholar 

  65. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol. 1990;3:120–8.

    CAS  PubMed  Google Scholar 

  66. Yasuda M, Katoh T, Hori S, Suzuki K, Ohno K, Maruyama M, Matsui N, Miyazaki S, Ogane N, Kameda Y. Endometrial intraepithelial carcinoma in association with polyp: review of eight cases. Diagn Pathol. 2013;8:25.

    Article  PubMed Central  PubMed  Google Scholar 

  67. McCluggage WG, Sumathi VP, McManus DT. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol. 2003;34:939–43.

    Article  CAS  PubMed  Google Scholar 

  68. Neto LC, Soares Jr JM, Giusa-Chiferi MG, Gonçalves WJ, Baracat EC. Expression of p53 protein in the endometrial polyp in postmenopausal women. Eur J Gynaecol Oncol. 2013;34:509–12.

    PubMed  Google Scholar 

  69. Miranda SP, Traiman P, Cândido EB, Lages EL, Freitas GF, Lamaita RM, Vidigal PV, da Silva Filho AL. Expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen. Int J Gynecol Cancer. 2010;20:1525–30.

    PubMed  Google Scholar 

  70. Koi C, Hachisuga T, Murakami M, Kurita T, Nguyen TT, Shimajiri S, Fujino Y. Overexpression of p53 in the endometrial gland in postmenopausal women. Menopause. 2015;22:104–7.

    Article  PubMed  Google Scholar 

  71. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.

    Article  CAS  PubMed  Google Scholar 

  72. Hickman ES, Helin K. The p53 tumour suppressor protein. Biotechnol Genet Eng Rev. 2000;17:179–211.

    Article  CAS  PubMed  Google Scholar 

  73. Aylon Y, Oren M. Living with p53, dying of p53. Cell. 2007;130(4):597–600.

    Article  CAS  PubMed  Google Scholar 

  74. Maia Jr H, Maltez A, Studart E, Athayde C, Coutinho EM. Ki-67, Bcl-2 and p53 expression in endometrial polyps and in the normal endometrium during the menstrual cycle. BJOG. 2004;111:1242–7.

    Article  PubMed  Google Scholar 

  75. Zubor P, Hatok J, Galo S, Dokus K, Klobusiakova D, Danko J, Racay P. Anti-apoptotic and pro-apoptotic gene expression evaluated from eutopic endometrium in the proliferative phase of the menstrual cycle among women with endometriosis and healthy controls. Eur J Obstet Gynecol Reprod Biol. 2009;145:172–6.

    Article  CAS  PubMed  Google Scholar 

  76. Taniguchi F, Kaponis A, Izawa M, Kiyama T, Deura I, Ito M, Iwabe T, Adonakis G, Terakawa N, Harada T. Apoptosis and endometriosis. Front Biosci (Elite Ed). 2011;3:648–62.

    Article  Google Scholar 

  77. Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, Fuchs-Young R. Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res. 2009;69:3405–14.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26–35.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of California San Diego, 200 West Arbor Drive, MC 8720, Room 2-120, San Diego, CA, 92103, USA

    Oluwole Fadare MD

  2. Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9072, USA

    Wenxin Zheng MD

Authors
  1. Oluwole Fadare MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenxin Zheng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oluwole Fadare MD .

Editor information

Editors and Affiliations

  1. Department of Pathology, University of California San Diego, San Diego, California, USA

    Oluwole Fadare

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fadare, O., Zheng, W. (2016). Precancerous Lesions of Endometrial Serous Carcinomas. In: Fadare, O. (eds) Precancerous Lesions of the Gynecologic Tract. Springer, Cham. https://doi.org/10.1007/978-3-319-22509-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22509-8_8

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22508-1

  • Online ISBN: 978-3-319-22509-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation